Kyowa Kirin Stock - analyst view and Nikkei 225 role on Wednesday
Published on 06/17/2026 at 21:45 | Editorial responsibility: Rafael MĂĽller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 21:41 JST. Details in the imprint.
Kyowa Kirin (JP3249600002) remains one of Japan’s notable mid-to-large cap pharma names on Wednesday as investors reassess its role in the Nikkei 225 and the latest analyst commentary on the stock. The focus today is on how the market views its earnings power and growth pipeline rather than on a single new headline.
All news and analysis on Kyowa Kirin stock
For a broader view of Kyowa Kirin’s financial disclosures and strategic moves, the topic page and the company’s Investor Relations site offer additional documents and updates.
How analysts currently view Kyowa Kirin
Sell-side coverage on Kyowa Kirin has been broadly constructive in recent months, with some houses pointing to its specialty drug portfolio and solid balance sheet as key supports for the investment case, even as Japan’s pharma sector faces pricing pressure.
In May, Jefferies reiterated a positive stance on Kyowa Kirin, highlighting the company’s earnings visibility and setting a price target around JPY 2,800, according to an analyst comment summary circulated to clients and reported in financial media.
Consensus and earnings expectations midweek
Across the market, consensus estimates still assume moderate top-line growth for Kyowa Kirin this year, driven by oncology and nephrology products, though the exact figures vary between data providers and are periodically updated after each quarterly release.
Investors are watching how the company delivers against its guidance and pipeline milestones, with particular attention to whether operating margins can be kept stable despite higher R&D spending and potential regulatory changes to drug pricing in Japan.
The product behind the stock
Kyowa Kirin generates most of its revenue from specialty pharmaceuticals, including its eczema treatment mogamulizumab and other biologic therapies in oncology, immunology and nephrology. The company focuses on niche indications where targeted drugs can command defensible pricing and long product cycles.
Where the stock trades today
Kyowa Kirin shares trade on the Tokyo Stock Exchange at JPY 2,447.00 as of 06/17/2026, 07:30 JST.
Key facts on Kyowa Kirin stock
- Company: Kyowa Kirin Co., Ltd.
- ISIN: JP3249600002
- Ticker: 4151
- Venue: TSE (Tokyo Stock Exchange)
- Price (as of 06/17/2026, 07:30 JST): 2,447.00 JPY
- Market cap: approximately 1.7 trillion JPY (as of 06/17/2026, based on latest price and shares outstanding)
- Sector / Industry: Health Care - Pharmaceuticals & Biotechnology
- Index membership: Nikkei 225, among others.
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
